Literature DB >> 1639440

Screening mouse mutations for resistance to cancer metastasis.

O S Egorov1, Y Liu, E E Sargent, G I Drizlikh, I K Egorov.   

Abstract

To search for host genes for resistance/susceptibility to cancer metastasis, mutation analysis was employed. Ten putative mutants of resistance to lymphoma EL4 and four putative mutants of resistance to sarcoma MCA/77-23 of C57BL/6J (B6) mice were produced. These mutants were designated S (for "survivor") mutants; they do not reject parental strain B6 skin grafts. S-mutants resist moderate tumor cell doses: TD50 values in them were increased by a factor of 12 to 600. Genetic linkage tests showed that five S-mutants were linked to mouse major histocompatibility complex (H-2) and five other S-mutants were not linked to this locus. A group of H-2-linked S-mutants resisting EL4 and a mutant, S-87/2, resisting MCA/77-23 were tested for resistance to spontaneous metastases of the same two tumors, EL4 and MCA/77-23. Two of the mutants, S-31 (lymphoma-resisting) and S-87/2 (sarcoma-resisting), were shown to carry mutations of mouse gene(s) for resistance to tumor metastases. In both of these mutants resistance to the original tumor transplant coexisted with highly increased susceptibility to metastasis. These mutants are a new tool to study genes for resistance to cancer metastasis and of mechanism of resistance controlled by each individual gene.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1639440     DOI: 10.1007/bf00215051

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  18 in total

1.  Differential cell surface antigen expression on metastatic variant lymphoma cell lines.

Authors:  S S Joshi; K W Brunson
Journal:  Oncology       Date:  1990       Impact factor: 2.935

Review 2.  A genetic model for colorectal tumorigenesis.

Authors:  E R Fearon; B Vogelstein
Journal:  Cell       Date:  1990-06-01       Impact factor: 41.582

3.  'Immune surveillance' without immunogenicity.

Authors:  Z Grossman; R B Herberman
Journal:  Immunol Today       Date:  1986-05

4.  Histocompatibility mutations in mice: chemical induction and linkage with the H-2 locus.

Authors:  I K Egorov; Z K Blandova
Journal:  Genet Res       Date:  1972-04       Impact factor: 1.588

Review 5.  Biology and genetics of hybrid resistance.

Authors:  M Bennett
Journal:  Adv Immunol       Date:  1987       Impact factor: 3.543

6.  Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice.

Authors:  C Uyttenhove; J Van Snick; T Boon
Journal:  J Exp Med       Date:  1980-11-01       Impact factor: 14.307

7.  Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells.

Authors:  A Leone; U Flatow; C R King; M A Sandeen; I M Margulies; L A Liotta; P S Steeg
Journal:  Cell       Date:  1991-04-05       Impact factor: 41.582

8.  A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells.

Authors:  U Günthert; M Hofmann; W Rudy; S Reber; M Zöller; I Haussmann; S Matzku; A Wenzel; H Ponta; P Herrlich
Journal:  Cell       Date:  1991-04-05       Impact factor: 41.582

9.  The E1a gene of adenovirus type 2 reduces the metastatic potential of ras-transformed rat embryo cells.

Authors:  R Pozzatti; M McCormick; M A Thompson; G Khoury
Journal:  Mol Cell Biol       Date:  1988-07       Impact factor: 4.272

10.  Studies in antibody response of mice to tumour inoculation.

Authors:  P A GORER
Journal:  Br J Cancer       Date:  1950-12       Impact factor: 7.640

View more
  2 in total

1.  Possible role of Abb gene in mouse resistance to EL4 metastases.

Authors:  O S Egorov; Y Liu; I K Egorov
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

2.  Immune cells from SR/CR mice induce the regression of established tumors in BALB/c and C57BL/6 mice.

Authors:  Janne Koch; Jann Hau; Jan Pravsgaard Christensen; Henrik Elvang Jensen; Morten Bagge Hansen; Klaus Rieneck
Journal:  PLoS One       Date:  2013-03-21       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.